SGLT2 INHIBITION AND STIMULATIION OF ENDOGENOUS GLUCOSE PRODUCTION Significance - PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria
Phase of Trial: Phase IV
Latest Information Update: 15 Jan 2020
Price : $35 *
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms PROTOCOL 3
- 30 Dec 2019 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 30 May 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.